# Cost-effectiveness of perioperative novel therapies for stage II to III non-small cell lung cancer in Sri Lanka

Source: https://onco.cc/key-papers/paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026/  
OnCo record `paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

At a threshold of US$6,700 per quality-adjusted life year, adjuvant osimertinib, adjuvant alectinib and neoadjuvant nivolumab were cost-effective in Sri Lanka; at US$3,000 only the osimertinib strategies remained so.

## Summary

A Markov cost-utility model from the Sri Lankan health system's perspective compared adjuvant, neoadjuvant, perioperative and consolidation targeted and immunotherapies for stage II to III NSCLC, with sex-specific analyses, a lifetime horizon and a 5-year budget impact for the therapies found cost-effective.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: BMJ Oncology
- Year: 2026
- DOI: 10.1136/bmjonc-2025-001046
- Authors: Joseph N, Kularatna S, Senanayake S.
- Findings: At US$6,700 per QALY, adjuvant osimertinib after surgery and after curative chemoradiotherapy, adjuvant alectinib after surgery and neoadjuvant nivolumab were cost-effective in both men and women.; At US$3,000 per QALY, only osimertinib-based strategies remained robustly cost-effective; the other therapies would need substantial price reductions.; The 5-year budget impact of adopting the cost-effective therapies under full implementation was about US$11.8 million.
- What it means: A worked example of how the free state system could rank costly lung cancer drugs and what price cuts would bring others within reach.
- Caveats: Model-based; conclusions were sensitive to lower, opportunity-cost-informed thresholds.

## Sources

- BMJ Oncology 2026: https://doi.org/10.1136/bmjonc-2025-001046
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42369562/

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- institutions: [Ministry of Health and Mass Media, Sri Lanka](https://onco.cc/institutions/sri-lanka-ministry-of-health/)

---
JSON: https://onco.cc/api/v1/entities/paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026.json